Literature DB >> 8144190

Cytokine-induced tumor immunogenicity: endogenous interleukin-1 alpha expressed by fibrosarcoma cells confers reduced tumorigenicity.

R N Apte1, A Douvdevani, M Zoller, R M White, T Dvorkin, N Shimoni, E Fima, M Hacham, M Huleihel, D Benharroch.   

Abstract

A direct correlation between the constitutive expression of IL-1 alpha and reduced tumorigenicity of fibrosarcomas was observed. This was established in fibrosarcoma cell lines which produce IL-1 alpha 'spontaneously', possibly as an aberration of oncogene-mediated transformation or upon IL-1 alpha gene transfer. In fibroblasts intracellular or membrane-associated IL-1 alpha is expressed, whereas the secreted form of the cytokine (IL-1 beta) is absent. Studies on the mechanisms of tumor regression of the IL-1 alpha-positive fibroblastoid cell lines indicated that IL-1 alpha potentiates the development of tumor cell-specific CTLs, which are of importance for tumor eradication. Thus, IL-1 alpha induces enhanced helper T cell activity which provides auxiliary signals for the growth/development of CTLs. Non-adaptive effector cells, activated locally by IL-1 alpha-expressing fibrosarcoma cells, also contribute to the eradication of IL-1 alpha-expressing fibrosarcomas. Local IL-1 alpha expression potentiated antigen presentation, by the malignant fibroblasts as well as by tissue-resident antigen-presenting cells, thus further potentiating anti-tumor immune responses. Mice, in which IL-1 alpha-producing tumors were regressed, developed an immune memory and rejected a challenge with an IL-1 non-producing violent tumor cell line. Endogenous IL-1 alpha activates a cytokine cascade (i.e., IL-6, CSF), produced by the malignant cells and possibly also by stromal cells. However, IL-1 alpha expression is essential for fibrosarcoma eradication, while other cytokines possibly amplify and sustain its action.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8144190     DOI: 10.1016/0165-2478(93)90163-v

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  7 in total

1.  The Interleukin (IL)-1R1 pathway is a critical negative regulator of PyMT-mediated mammary tumorigenesis and pulmonary metastasis.

Authors:  Maryse Dagenais; Jeremy Dupaul-Chicoine; Todd Douglas; Claudia Champagne; Alexandre Morizot; Maya Saleh
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

Review 2.  Historical insights into cytokines.

Authors:  Charles A Dinarello
Journal:  Eur J Immunol       Date:  2007-11       Impact factor: 5.532

3.  Mechanisms of cytokine production by fibroblasts-implications for normal connective tissue homeostasis and pathological conditions.

Authors:  R N Apte
Journal:  Folia Microbiol (Praha)       Date:  1995       Impact factor: 2.099

4.  Expression of interleukin-1 (IL-1) ligands system in the most common endometriosis-associated ovarian cancer subtypes.

Authors:  Mamadou Keita; Paul Bessette; Manuella Pelmus; Youssef Ainmelk; Aziz Aris
Journal:  J Ovarian Res       Date:  2010-01-28       Impact factor: 4.234

5.  Multiple effects of transfection with interleukin 2 and/or interferon gamma on the behavior of mouse T lymphoma cells.

Authors:  A B Geldhof; J Van Ginderachter; P Vandersteen; G Raes; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1998-07       Impact factor: 5.150

6.  IL-1 is required for tumor invasiveness and angiogenesis.

Authors:  Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-21       Impact factor: 11.205

7.  Undetected Jawbone Marrow Defects as Inflammatory and Degenerative Signaling Pathways: Chemokine RANTES/CCL5 as a Possible Link Between the Jawbone and Systemic Interactions?

Authors:  Johann Lechner; Marlene Schmidt; Volker von Baehr; Fabian Schick
Journal:  J Inflamm Res       Date:  2021-04-21
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.